All PlansCoverageMedium impact
Allogeneic Hematopoietic Cell Transplantation for Genetic Diseases and Acquired Anemias
Blue Cross & Blue Shield of Mississippi·Hematology, Oncology, Pediatrics·Medical Policy
We identified it
Jun 20, 2026
Summary
This is a new comprehensive medical policy defining coverage criteria for allogeneic hematopoietic cell transplantation (allo-HCT) for genetic diseases and acquired anemias, including conditions like sickle cell disease, thalassemia, bone marrow failure syndromes, and inherited metabolic disorders. The policy establishes the medical necessity framework for these specialized transplant procedures.
Action Required
Immediately: Review cases involving allogeneic hematopoietic cell transplantation for genetic diseases and acquired anemias to ensure they meet the newly defined medical criteria outlined in policy L.8.01.412. Clinical documentation must support medical necessity for covered conditions including sickle cell disease, thalassemia, bone marrow failure syndromes, primary immunodeficiencies, inherited metabolic disorders, and osteopetrosis. Providers should familiarize themselves with the specific diagnostic criteria for covered conditions to ensure proper case selection and documentation.